last week attend precis crispr genom edit congress boston new
clinic data present updat current state crispr field spoke wide
versatil broad util crispr platform relev topic highlight note
includ util crispr vitro well vivo screen platform abil
engin protein variant superior select edit abil non-vir methodolog
crispr deliveri also heard present crispr nasdaqgm crsp
exon therapeut privat carib bioscienc privat casebia therapeut privat
multiplex edit effici produc allogen car-t cell enhanc therapeut t-cell function
allogen car-t allow immedi treatment without risk manufactur failur
autolog therapi patient present cell remov via apheresi manufactur begin singl treatment week
allogen allow immedi treatment sinc t-cell deriv healthi donor
donor cell select favor phenotyp factor correl complet respons
crispr edit allogen t-cell design improv persist allo set ko elimin mhc express prevent gvhd via tcr
disrupt improv safety/pot precis insert construct trac locust
consist high level edit across differ program car-t program
effici deplet tcr cell manufactur import gvhd
see detect cell outgrowth absenc cytokin growth serum cytokin indic crispr engin cell dont
growth indic transform
edit allow consist product consist high edit across differ donor cell desir edit
greater consist viral approach car rang crispr lentivir car-t
car-t cell demonstr potent specif cytotox vitro
elicit xenogen gvhd ind-en studi
provid prolong surviv day mous model
notabl reduc tumor volum mice vs untreat control
analyst certif disclosur pleas see page
re-challeng assay given right flank without car-t see increas tumor volum volum diminish treat mice re-challeng
opposit flank day later re-inject tumor cell mice receiv car-t didnt show tumor growth
gener novel candid use crispr
use multiplex edit singl shot sextupl ko plu insert perform high effici
speed discoveri week concept id put target make cart-t cell month concept vivo preclin poc
gene edit treat duchenn muscular dystrophi
use singl cut crispr neuromuscular diseas
dystrophin connect muscl contractil unit plasma membran allow muscl damag activ found around plasma membran
serv shock absorb prevent damag activ
dmd hot spot mutat region constitut mainli delet amend singl cut gene edit
focus hot spot region
delet exon edit exon allow skip exon refram applic patient
select guid mous human cell line vitro test human dmd ipsc cell vivo deliveri sgrna
sgrna vector restor dystrophin express seen dmd cardiomyocyt
mous model detect target tissu muscle/heart liver
sequenc conserv anim model human make speci specif guid mice dog
restor dystrophin ko mice administr
robust express week post administr
protein restor correct diseas histolog mice
restor function reduc ck level level wt week
spontan mutat occur dog spontan dog dmd model
plan long term care studi dog
protein express histolog correct diseas histolog seen dog muscl week post-administr
believ level enough restor clinic manifest
next-gener gene edit technolog allogen cell
crispr edit enabl target specif chang varieti cell type
engin guid rna basi next-gen genom edit technolog
crispr hybrid rna-dna chrnda rna-dna hybrid guid enabl precis edit nucleas
retain high on-target edit effici chrdna significantli reduc off-target edit rel first-gen crispr human primari
issu us patent relat chrdna expiri
high fidel nucleotid pattern empir data use inform chrdna engin screen guid enabl select top candid
valid on-target/off-target edit
select identif tag dna end sequenc site-seq assay
methodolog provid comprehens list cellular off-target site
target specif demonstr potenti off-target site queri edit cell five site demonstr edit limit
detect crrna reagent none site detect edit chrdna reagent
direct deliveri complex done nucleofect vitro
consist edit seen cell edit across multipl cell donor experi low variabl edit efficaci
allogen car-t cell therapi b-cell malign
aav-medi site-specif insert locu
modif result ko tcr prevent gvhd
edit result persist t-cell polyfunction tumor cell interact
demonstr specif vitro polyfunction model dlbcl
gene therapi gene edit retin diseas
aav vector intra-ocular gene deliveri
safeti profil aav human trial
long-term express rodent canin nhp human eye
subretin therapi approv fda
numer on-going aav-bas trial eye
intravitr inject transduc rpe/photoreceptor subretin inject effici transduc rpe mice
nhp transduct aav intravitr inject transduc primarili around fovea penetr past first layer retin ganglion cell
vector provid sustain dose-depend gene express eye
express secret anti-vegf protein shown month dose nhp efficaci model
treatment improv retin integr patient wet-amd
casebia joint ventur crispr ip contribut bayer contribut ownership
ventur partner first right opt upon ind accept compani allow consid third-parti offer well
focu vivo deliveri gene edit liver eye ex vivo cell engin regulatori t-cell
focu autosom domin retin pigmentosa
strategi develop guid rna select target destroy human mutant allel
critic select edit mutant allel wt allel lack wt rhodopsin lead photoreceptor death
engin target cut site vector creat vivo self-inactiv system may way avoid long-term express
use studi doubl strand break dsb repair
reason studi dsb repair cancer
synthet lethal cancer defici doubl strand break repair pathway exploit therapeut gain
defici one pathway lead trade-off toward pathway
target back-up dsb repair pathway emerg therapeut strategi
doubl strand break primari lethal lesion creat commonli use cancer therapeut radiat chemo
non-homolog end join nhej primari repair pathway dsb creat nt delet homolog recombin hr singl
strand anneal ssa microhomology-medi end join mmej also play role
current dsb assay method limit
vector-bas assay requir creation special cell line integr cassett limit applic
readout limit reconstitut gfp express cassett
measur pathway time cell
dna-damag induc foci measur pathway intermedi rather complet repair
system use studi dsbr pathway dsbr-seq dsbr-ddpcr
read accur quantifi nhej mmej separ
three pathway assess simultan transfect cell
numer role dsb repair includ promot end-resect
look answer suppressor promot mmej literatur contradictori
promot mmej dsbr-seq
differ frequenc microhomolog usag shown mutat cancer genom
also look understand mechan hpv-associ tumor radio-sensit
protein suppress nhej promot mmej provid rational clinic radio-sensit hpv-associ cancer
engin crispr enzym superior properti
crispr employ perman genom edit well transient epigenom edit
use protein engin impart desir properti
mani differ enzym crispr toolbox
target rang dictat protospacer-adjac motif pam sequenc
requir extens t-rich sequenc found less frequent human genom vs pam
structure-guid engin use improv target rang
engin protein expand target rang relax pam prefer fold improv on-target activ
fold improv base editor activ enhanc activ lower temp
engin strategi use optim ca variant
single-allel edit challeng allele-specif edit requir right target rang proper activ high specif
rang expand via protein engin alter pam select relax pam expand
engin variant pam select
identif essenti gene cancer immunotherapi use high-throughput genom engin
lot cancer-focus sequenc project exist data
abil perturb interrog genet variant lag behind sequenc
variant caus cancer/cr drug resist rapidli understand effect mani variant
har dna edit large-scal function genom studi
typic chang gene interest extract phenotyp chang
look phenotyp ask gene interest access noncod non-transcrib genom element crispr
programm take advantag microarray synthesi techniqu produc guid rna
genome-scal crispr knock-out gecko screen target ko gene human genom
idea target differ gene take advantag nhej-medi error-pron repair creat loss-of-funct mutat
cell receiv one crispr construct/genet perturb cell subject phenotyp select process surviv cell analyz
gecko display high consist reagent target gene compar genome-wid crispr screen compar genome-wid
found tremend consist guid rna target gene littl consist hairpin target gene
ask mutat promot metastasi want address vivo screen given higher clinic relev
use crispr screen creat mutant cell pool transplant subcutan mice
could analyz develop tumor differ time point identifi mutant pool drive tumor metastas growth differ
stages/ differ organ
screen doesnt provid understand mechan behind dna hit given complex vivo environ
need bridg gap vitro vivo cancer model
antigen-process mutat tumor cell shown prevent respons immunotherapi patient
creat gecko librari use perform two cell-typ genome-scal crispr screen resist cell cytolysi
top two hit hla-a two essenti compon mhc also identifi gene part proteasom known interfer
antigen present
perform vivo crispr-en screen well identifi apelin receptor gene yield io resist block t-cell mediat cytolysi part
goal predict tumor would less like respond therapi base mutat person medicin
genom edit vivo rnp donor dna complex gold nanoparticl
deliv rnp donor dna vivo challeng involv deliv compon protein associ guid rna dna
homolog repair
problem effici deliveri solv yet
viral deliveri rnp donor dna pose challeng
sustain express increas potenti off-target effect
foreign protein potenti mhc-mediat immun activ tissu destruct upon prolong express
requir multipl virus one donor guid nucleotid second protein must effici enter cell anim
accomplish titer higher accept clinic dose
deliv rnp donor dna via non-vir method interest challeng
lipofectamin work effici studi focus ko repair
combin viral/non-vir use aav guid donor nucleotid mrna platform lipid nanoparticl
crispr-gold design deliv rnp donor dna
investig gene edit via crispr-gold system mdx mous model dmd
crispr-gold inject muscl tissu along cardiotoxin hdr occur effici divid cell ad damag agent like
cardiotoxin muscl tissu induc muscl cell prolifer
mutat correct shown crispr-gold hdr effici therapeut relev
dystrophin express also observ histolog treatment crispr-gold
minim off-target dna damag highest error rate
improv muscl strength note via forelimb hang test multipl inject improv notabl significantli lower
wt
genedit gene therapi deliveri compani found base tech
deliveri brain challeng
local deliveri may possibl intercrani inject advantag includ avoid bbb one-tim therapi
crispr-gold inject mice striatum hippocampu
edit striatum post-deliveri visual via tdtomato express
cell express tdtomato deliveri
investig nhej neuron crispr-gold inject hippocampu
edit effici close inject site b/c local natur deliveri
shown gener nhej neuron
look fragil relat autism caus triplet repeat expans gene
signal implic diseas well mani differ neurolog patholog
design construct inject striatum mous model
crispr-gold significantli reduc posit cell brain
look behavior effect post edit well model mice display marbl buri behavior significantli decreas post treatment
model mice also jump behavior significantli reduc post edit well
affect phenotyp aris part brain line cross aris hippocampu gene edit local striatum
anoth strategi deliveri involv chemic conjug delivery-compet manner conjug
conjug ccpp difficult chemic modifi may inactiv
group develop trailer reduction-sensit linker amin modif allow multipl cpp conjug protein interest
releas half-lif minut
activ reduction/releas nucleas activ almost
gene edit perform hek cell system intern cell edit effici
synergi crispr function genom human genet enhanc biopharmaceut pipelin success
improv product challeng industri
phase ii bottleneck exist major reason lack efficaci
cumul financi opportun cost lead phase ii enorm
meet challeng requir har power human genet evid intern research capabl
establish still evolv
develop appli function genom platform technolog drug discoveri
discov valid novel therapeut target across ta immunolog neurosci oncolog
build pool screen platform first array platform
deliv new target pipelin first unbias screen human genetics-en approach
develop techniqu pathophysiolog relev vitro vivo discoveri model assay
decid build/outsourc
oper build vs outsourc
start end mind deliv target pipelin quickli
build assay develop screen hit follow-up data analysi therapeut hypothesi gener test cell line gener
outsourc crispr librari reagent gener molecular biolog cell line gener anim model
extern foundat genom edit tech core busi speed academ innov
intern assay deliveri method pathophysiolog relev discoveri system
intern induc screen primari cells/ipsc vivo screen array screen platform human genet variant
take advantag exist cell line constitut induc screen
util vivo crispr model io/immunolog
risk invest
investor consid risk invest stock high risk high volatil clinic stage asset may success
clinic trial may fail gain regulatori approv product launch possibl revenu meet investor expect
product face unexpect competit revenu approv product may also meet investor expect approv one diseas
alway correl success approv anoth diseas overal market condit may also affect valu underli secur
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
